Table 1.
Baseline sociodemographic characteristics of 197 women enrolled in the Ring Study in southwestern Uganda between 2013 and 2016
| Variable | All | Intravaginal practices | P value | |
| No | Yes | |||
| n (%) | n (%) | n (%) | ||
| Overall | 197 | 104 (52.8) | 93 (47.2) | |
| Trial arm | 0.835 | |||
| Dapivirine vaginal ring | 132 (67.0) | 69 (66.4) | 63 (67.7) | |
| Placebo | 65 (33.0) | 35 (33.6) | 30 (32.3) | |
| Age (years) | 0.275 | |||
| 18–24 | 66 (33.5) | 30 (28.8) | 36 (38.7) | |
| 25–34 | 98 (49.8) | 57 (54.8) | 41 (44.1) | |
| 35+ | 33 (16.7) | 17 (16.4) | 16 (17.2) | |
| Education level | 0.276 | |||
| Incomplete primary school | 68 (34.5) | 37 (35.6) | 31 (33.3) | |
| Complete primary school | 105 (53.3) | 58 (55.8) | 47 (50.5) | |
| Secondary school* | 24 (12.2) | 9 (8.6) | 15 (16.1) | |
| Marital status | 0.020 | |||
| Single and never married | 90 (45.7) | 38 (36.5) | 52 (55.9) | |
| Single but previously married | 25 (12.7) | 14 (13.5) | 11 (11.8) | |
| Married | 82 (41.6) | 52 (50.0) | 30 (32.3) | |
| Number of life time sex partners | 0.002 | |||
| Median (IQR) | 6 (4–12) | 5 (3–9) | 8 (5–20) | |
| Has main partner | 0.194 | |||
| No | 35 (17.8) | 15 (14.4) | 20 (21.5) | |
| Yes | 162 (82.2) | 89 (85.6) | 73 (78.5) | |
| Duration lived with main partner (years) | 0.690 | |||
| <1 | 35 (21.6) | 17 (19.1) | 18 (24.7) | |
| 1–2 | 34 (21.0) | 19 (21.3) | 15 (20.5) | |
| 3+ | 93 (57.4) | 53 (59.6) | 40 (54.8) | |
| Lived with (main) partner in the past year | 0.171 | |||
| All the time | 48 (37.8) | 38 (42.7) | 24 (32.9) | |
| Some of the time | 14 (11.0) | 7 (7.9) | 12 (16.4) | |
| No | 65 (51.2) | 44 (49.4) | 37 (50.7) | |
| Currently lives with main partner | 0.376 | |||
| No | 87 (53.7) | 45 (50.6) | 42 (57.5) | |
| Yes | 75 (46.3) | 44 (49.4) | 31 (42.5) | |
| Unprotected sex with multiple/new partner in the past 3 months | ||||
| No | 38 (19.3) | 18 (17.3) | 20 (21.5) | 0.456 |
| Yes | 159 (80.7) | 86 (82.7) | 73 (78.5) | |
| Drug/alcohol use in the past 3 months | ||||
| No | 48 (24.4) | 32 (30.8) | 16 (17.2) | 0.027 |
| Yes | 149 (75.6) | 72 (69.2) | 77 (82.8) | |
| Baseline STI/BV status | ||||
| TV | ||||
| Negative | 121 (61.4) | 61 (58.7) | 60 (64.5) | 0.399 |
| Positive | 76 (38.6) | 43 (41.3) | 33 (35.5) | |
| NG | ||||
| Negative | 173 (87.8) | 92 (88.5) | 81 (87.1) | 0.770 |
| Positive | 24 (12.2) | 12 (11.5) | 12 (12.9) | |
| CT | ||||
| Negative | 177 (89.8) | 97 (93.3) | 80 (86.0) | 0.093 |
| Positive | 20 (10.2) | 7 (6.7) | 13 (14.0) | |
| BV | ||||
| Negative | 191 (96.9) | 102 (53.4) | 89 (46.6) | 0.332 |
| Positive | 6 (3.1) | 2 (33.3) | 4 (66.7) | |
*Includes one woman who had greater than secondary education.
BV, bacterial vaginosis; CT, Chlamydia trachomatis; NG, Neisseria gonorrhoeae; STI, sexually transmitted infection; TV, Trichomonas vaginalis.